Bluebird Inks Genome Editing Research Deal With Novo Nordisk
Zacks Investment Research | Oct 09, 2019 11:17PM ET
bluebird bio, Inc. (NASDAQ:BLUE) announced that it has entered into a research collaboration agreement with Denmark’s Novo Nordisk (CSE:NOVOb) A/S (NYSE:NVO) for jointly developing next-generation in vivo genome editing therapies for addressing genetic diseases including hemophilia.
The research collaboration will span over a period of three years and focus on developing a gene therapy candidate for offering hemophilia A patients with a lifetime free of factor replacement therapy. Financial terms of the deal were not disclosed.
The deal will leverage bluebird’s proprietary mRNA-based megaTAL gene editing technology with Novo Nordisk’s hemophilia portfolio. It will initially focus on correcting FVIII-clotting factor deficiency with the potential to explore additional therapies.
With this research pact, both companies are looking to develop a treatment to substantially reduce the burden of disease for patients with factor VIII deficiency. bluebird will get a strong partner in Novo Nordisk.
Shares of bluebird have lost 9.1% so far this year, compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.